Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Expected to Rise, HC Wainwright Analyst Says

Karyopharm Therapeutics (NASDAQ:KPTI) had its price objective upped by stock analysts at HC Wainwright from $7.00 to $56.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q1 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.10) EPS, FY2026 earnings at ($0.87) EPS and FY2027 earnings at ($0.46) EPS.

Several other research analysts also recently commented on the stock. Piper Sandler raised their price objective on shares of Karyopharm Therapeutics from $60.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. StockNews.com downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $45.00 price objective on shares of Karyopharm Therapeutics in a report on Thursday, February 20th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Karyopharm Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $62.75.

Karyopharm Therapeutics Stock Down 15.1 %

Shares of KPTI stock opened at $8.35 on Wednesday. The company has a 50 day moving average of $9.85 and a 200-day moving average of $11.28. Karyopharm Therapeutics has a 12-month low of $7.61 and a 12-month high of $25.50. The firm has a market cap of $70.31 million, a P/E ratio of -8.19 and a beta of 0.06.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Wednesday, February 19th. The company reported ($3.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.90) by $0.30. The company had revenue of $30.54 million for the quarter, compared to analysts’ expectations of $30.29 million. As a group, equities analysts expect that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. boosted its holdings in Karyopharm Therapeutics by 46.3% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 6,319,842 shares of the company’s stock valued at $4,274,000 after purchasing an additional 2,000,000 shares during the period. Marshall Wace LLP boosted its holdings in Karyopharm Therapeutics by 15.3% in the 4th quarter. Marshall Wace LLP now owns 2,401,413 shares of the company’s stock valued at $1,633,000 after purchasing an additional 319,187 shares during the period. GSA Capital Partners LLP boosted its holdings in Karyopharm Therapeutics by 80.6% in the 3rd quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock valued at $1,474,000 after purchasing an additional 792,283 shares during the period. Geode Capital Management LLC boosted its holdings in Karyopharm Therapeutics by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 1,392,314 shares of the company’s stock valued at $942,000 after purchasing an additional 36,922 shares during the period. Finally, Jane Street Group LLC boosted its holdings in Karyopharm Therapeutics by 265.5% in the 4th quarter. Jane Street Group LLC now owns 748,306 shares of the company’s stock valued at $506,000 after purchasing an additional 543,556 shares during the period. 66.44% of the stock is owned by institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).